ArticlePediatric nephrology (Berlin, Germany)2026
Clinical value of repeat kidney biopsy in pediatric IgA vasculitis nephritis.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond treatment adjustment: clinical utility of repeat kidney biopsy in pediatric IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFor pediatric patients with IgA vasculitis nephritis (IgAVN), therapeutic decisions during relapse are often guided by empirical adjustments based on clinical manifestations, lacking timely pathological evidence. We aimed to investigate the dynamic evolution of kidney pathology in children with IgAVN and evaluate the clinical utility of repeat kidney biopsy in treatment decisions.
methodsRetrospective analysis was conducted on 30 children with IgAVN who underwent repeat kidney biopsy. We summarized demographic characteristics, clinical relapse features, and indications for repeat kidney biopsy. Clinical indicators and kidney pathological changes were compared from initial to repeat kidney biopsy, and correlation between clinical indicators and pathological progression was analyzed. Longitudinal progression after treatment adjustments based on repeat kidney biopsy findings was assessed using linear mixed-effects model (LMM).
resultsMedian interval between the two kidney biopsies was 39.95 months. During this period, despite no significant changes in 24-h urinary protein (24 h UTP) and urinary red blood cell (URBC) levels, estimated glomerular filtration rate (eGFR) showed a slight increasing trend (141.68 vs. 167.37 mL/min/1.73 m
conclusionA distinct dissociation exists between clinical presentation and kidney pathological progression during relapse in children with IgAVN. Repeat kidney biopsy is particularly beneficial for pediatric patients with clinical relapse whose conditions cannot be accurately assessed by conventional indicators; it facilitates enhanced treatment precision and improves long-term kidney outcomes.
Indexed as
Identifiers
42373959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.